Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture (ALLOB-TF2)
Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture
Sponsor: Bone Therapeutics S.A
This PHASE2 trial investigates Tibial Fracture and is currently ongoing. Bone Therapeutics S.A leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
May 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Sep 2021 — May 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bone Therapeutics S.A
- ICON plc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Anderlecht, Belgium , Badalona, Spain , Barcelona, Spain , Brest, France , Budapest, Hungary , Chambray-lès-Tours, France , Eger, Hungary , Genk, Belgium , Giessen, Germany and 23 more locations